Stories
Prime pharmacists address AMCP virtual conference as keynote speakers
Catherine Starner, PharmD and Nicole Kjesbo, PharmD discuss the specialty drug pipeline and forecast
April 23, 2021To determine the pipeline and forecast, Starner and Kjesbo consider cost, population/prevalence and management strategies – such as utilization management, prior authorizations and quantity limits. For inclusion on the Watch List, Prime generally focuses on drugs that are submitted to the U.S. Food and Drug Administration (FDA) and have a high anticipated spend based on per member per month (PMPM). Prime forecasts drugs on both medical and pharmacy benefits to help manage total drug spend for its health plan clients.
Starner and Kjesbo focused on pipeline and forecasting for:
While gene therapy approvals have been few and far between, there are more on the horizon. Possible gene therapy reviews include:
- Eladocagene exuparvovec, PTC Therapeutics – aromatic l-amino acid decarboxylase (AADC) deficiency
- SRP-9001, Sarepta Therapeutics – Duchenne muscular dystrophy (DMD)
- AMT-061 (etranacogene dezaparvovec), uniQure – hemophilia B
Prime publishes monthly decisions expected from the FDA and monthly pipelines.
Related news
Stories
May 25, 2022
Three Minutes with Kelly Pokuta
Dr. Kelly Pokuta is vice president, trade relations & strategy and chief trade…
Stories
May 23, 2022
Biosimilar use alone won’t cut drug costs
We see it time after time. High-potential innovation that just doesn’t seem to…
Stories
May 13, 2022
Prime expert showcases medical specialty drug management solutions
Prime Therapeutics’ (Prime) Chris Ford, assistant vice president, strategy and innovation, was a…